STOCKHOLM, Dec. 23, 2020 /PRNewswire/ -- C-RAD has now
received the purchase order from the Belgium company Ion Beam Applications SA
(IBA), regarding the supply of C-RAD's surface tracking solution
for Shenzhen proton therapy
center. The purchase order includes multiple Catalyst™
systems and a Sentinel™ 4DCT system including a
multiyear service agreement.
In June 2020 C-RAD and IBA signed
a letter of Intent for the supply of the Catalyst and Sentinel
systems for this project. Since June C-RAD and IBA worked on the
supplier evaluation process. The successful finalization was a
pre-requisite for the purchase agreement.
Shenzhen Tumor Hospital is a member of the Chinese Academy of
Medical Sciences (CAMS). CAMS is a leading health network for
cancer prevention and treatment in China, which is active in cancer research,
comprehensive education and research-based prevention. C-RAD has
already a Catalyst installation with a photon treatment system at
the CAMS site in Beijing.
"China has a very progressive
proton therapy program. We are excited to be selected vendor of
choice for this prestigious project. We are looking forward to work
with the CAMS team and IBA on the implementation for this first
joint project in China," says
Tim Thurn, CEO and President at
C-RAD AB. "In proton therapy high precision and accurate patient
positioning are crucial for the treatment success. Our dedicated
solution for motion management within proton therapy and the
cooperation with leading cancer centers supports our market leading
position in China."
The order has a total net value of approximately 12 MSEK and
will be recognized as order intake in the fourth quarter. The
schedule for delivery and installation of the C-RAD system is
expected to be set during 2021.
About C-RAD
C-RAD develops innovative solutions for use in advanced
radiation therapy. The C-RAD group offers products and solutions
for patient positioning, tumor localization and radiation treatment
systems. All product development is conducted in three fully owned
subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD
Innovation AB, all of which are located in Uppsala, Sweden. C-RAD has established three companies
for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD (Shanghai) Medical Devices Co Ltd. In
China. Cyrpa International SPRL, a
Franco-Belgian laser company, is a wholly owned subsidiary whose
operations are integrated. C-RAD AB is listed on NASDAQ Stockholm.
For more information on C-RAD, please visit
http://www.c-rad.com.
For further information:
Tim Thurn, CEO C-RAD AB, Phone
+46-18-666930, Email investors@c-rad.com
This information is information that C-RAD AB (publ) is obliged
to make public pursuant to the EU Market Abuse Regulation. The
information was submitted for publication at 13:30 CET on December 23,
2020.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/c-rad/r/shenzhen-proton-therapy-treatment-center-selects-c-rad-catalyst--system,c3261331
The following files are available for download:
|
https://mb.cision.com/Main/13008/3261331/1353779.pdf
|
Release
|
View original
content:http://www.prnewswire.com/news-releases/shenzhen-proton-therapy-treatment-center-selects-c-rad-catalyst-system-301198073.html
SOURCE C-RAD
